---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036391"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:58:18.572339+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance

## Summary
- Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.
- Received 180-day extension until September 22, 2024 to regain $1.00 minimum bid price compliance.
- Company had failed to meet bid price requirement by March 25, 2024 compliance date.
- GLTO continues trading under same symbol; reverse stock split is under consideration.
- If not compliant by September 22, Nasdaq may delist; company could appeal to hearings panel.

## SEC filing metadata
- accession: 0000950170-24-036391
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017024036391/0000950170-24-036391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017024036391/glto-20240322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036391
- JSON: https://secwatch.observer/filing/0000950170-24-036391.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036391.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.